ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.
- Mechanism
- Curator reviewed
ASI402 is an antibody (humanised HMFG1) that targets and binds to a protein called MUC1. This protein is exposed only on the surface of cancer cells, so the antibody binds specifically to tumours. Evidence suggests that the antibody then recruits components of the immune system called 'natural killer cells' to attack the cancer cells. ASI402 has broad potential because the MUC1 protein that it targets is made by many different types of cancer.
- Primary indication
- Investigated for use/treatment in breast cancer.Curator reviewed
- Also known as
- Epitumomab · IMMUNOGLOBULIN G1, ANTI-(HUMAN EPISIALIN) (HUMAN-MOUSE MONOCLONAL HMFG-1 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL HMFG-1, DIMER · IMMUNOGLOBULIN G1, ANTI-(HUMAN EPISIALIN) (MOUSE MONOCLONAL HMFG-1 .GAMMA.1-CHAIN), DISULFIDE WITH MOUSE MONOCLONAL HMFG-1, DIMER · SONTUZUMAB
- Code names
- AS-1402 · ASI402 · BTH-1704 · HUHMFG-1 · R-1550
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with ASI402, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account